Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. The Neulasta formulation involves Filgrastim (Neupogen) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life.
- "Do not administer Neulasta between 14 days before and 24 hours after administration of cytotoxic chemotherapy."
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
- Pegfilgrastim (Neulasta) package insert
- Pegfilgrastim (Neulasta) patient drug information (Chemocare)
- Pegfilgrastim (Neulasta) patient drug information (UpToDate)
History of changes in EMA indication
- 2022-08-22: Initial authorization
Also known as
- Generic names: pegylated GCSF, pegylated G-CSF, pegylated granulocyte colony stimulating factor
- Brand names: G-Lasta, Neulasta, Neupopeg, Onpro